Relatively high inter-patient variability of absorbed doses in tumor lesions has previously also been reported in several studies for [177Lu]Lu-PSMA-617 as well as for other PSMA ligands as e.g. [177Lu]Lu-PSMA I&T 50,52,53. This evidence concerns the gene FOLH1 and neoplasm.